What is the current Iran Diabetes Drugs and Devices Market size?

August 2022: Tirzepatide, A weight-loss drug, is now available in UAE to treat Type 2 diabetes. Mounjaro, or Tirzepatide, is a US Food and Drug Administration-approved injectable prescription medication used to improve blood sugar, or glucose, through weight loss.
February 2022: Abbott said it has tied up with various health-tech firms like BeatO Sugar.fit, PharmEasy, GOQii, 1MG, and Zyla for diabetes care. The company said it has also joined hands with Health, HealthifyMe, and Fitterfly under the initiative.

The Iran Diabetes Drugs and Devices Market is projected to register a CAGR of greater than 4.32% during the forecast period (2024-2029) Read More

Who are the key players in Iran Diabetes Drugs and Devices Market?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the Iran Diabetes Drugs and Devices Market. Read More

What years does this Iran Diabetes Drugs and Devices Market cover?

The report covers the Iran Diabetes Drugs and Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Iran Diabetes Drugs and Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Iran Diabetes Drugs and Devices Market Share

Statistics for the 2023 & 2024 Iran Diabetes Drugs and Devices market share, created by Mordor Intelligence™ Industry Reports. Iran Diabetes Drugs and Devices share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Iran Diabetes Drugs and Devices Industry

Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist in enabling insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products.